deliv modestli better-than-anticip result organ
growth slightli exceed forecast quarter
compani achiev improv perform key knee divis
organ versu estim driven
new product launch activ slightli better market growth knee well
suppli recoveri sale forc invest revenu
line compani adjust gross margin exceed forecast
bp year-over-year versu estim aid foreign currenc
hedg gain help off-set higher net interest expens
expect lead modest adjust ep upsid quarter versu
forecast consensu expect
follow favor result rais impli organ growth
forecast notabl compani expect
organ growth in-lin weight averag market growth rate
posit start rather prior assumpt
although believ estim consensu alreadi reflect
addit lower adjust tax rate assumpt
although compani plan use tax
save reinvest sale forc expans particularli special
sale repres initi effort acceler
revenu growth plan reinvest led lower adjust
oper margin outlook lower half prior rang versu
previous increas low end adjust ep
guidanc
continu expect level adjust oper margin
expans said compani anticip adjust gross margin
declin level given magnitud benefit realiz
foreign currenc hedg gain year bp adjust gross
margin contribut current expect continu
rais adjust ep estim
reflect improv organ growth adjust tax rate assumpt
also lower adjust ep forecast compani
reflect less adjust oper margin expans
total debt total asset
expect low head earn releas given
lacklust joint replac result mid-jun announc
cfo florin decis retir given backdrop modestli better-than-
consensu result includ sign improv compani key
knee implant divis clear posit said view
risk/reward balanc mix follow stock run-up friday
maintain neutral rate
import pleas read disclosur disclaim page report
report adjust ep consensu expect higher
estim slightli better-than-expect organ growth gross margin minor interest account
upsid rel adjust ep forecast quarter
zbh revenu declin year-over-year million consensu expect
million estim million quarter compani organ growth
slightli higher forecast currenc chang reduc revenu growth year-over-
year notabl partial less sale day quarter weigh organ growth perform
adjust incom statement analysisnorthcoast research million except percent per share sg interest expens interest expens incom incom incom margin com share compani report northcoast research estim factset
product categori standpoint better-than-anticip perform zbh knee dental
busi drove upsid rel organ growth estim help off-set modest
weak hip spine/cmf notabl call suppli recoveri one factor aid improv
result believ compani also benefit sale forc invest strong market condit
segment particular highlight surgic upper extrem primarili shoulder implant
 busi rel strong quarter addit zbh dental organ growth turn
posit organ first time sinc compani attribut traction
invest made late last year neg note spine/cmf sale weaker anticip
reflect tougher comparison continu weak spine follow late sale forc chang notabl
expect inflect point spine busi earli sale forc chang
anniversari compani better abl support rosa spine launch rosa manufactur capac
primarili use support rosa knee launch
inc organ growth analysi reflect pro forma result zimmer biomet compani report northcoast organ growth analysisnorthcoast currenc constant currenc acquisit divestitur organ hip knee spine cmf dental compani report northcoast research estim knee post organ growth estim quarter knee
implant market growth appear stronger level current model versu last
quarter zbh market share loss appear narrow geograph standpoint zbh asia
pacif emea knee implant busi remain rel steadi organ
basi respect america knee segment meaning improv versu
neg despit difficult year-over-year comparison quarter contribut
rosa knee robot surgeri system sale includ knee revenu appear modestli stronger
quarter wound guess versu compani core knee implant busi also
improv quarter aid product launch includ persona cementless knee persona revis
knee notabl new product expect aid product mix standpoint given price premium
cementless knee robot increment consum revenu per procedur
revis knee roughli price point primari knee less price pressur
hip post posit organ growth modestli forecast similar
knee post improv america result hip implant busi quarter versu
despit difficult comparison view encourag given concern would see
weak hip larg joint sale repres focus effort compani new knee product
howev modest improv america off-set weak zbh emea
organ asia pacif organ hip busi product standpoint point
upcom launch product use anterior approach potenti catalyst hip divis
inc knee organ growth analysi reflect pro forma result zimmer biometsourc compani report northcoast
zbh adjust oper margin declin bp year-over-year slightli
forecast quarter adjust gross margin improv bp year-over-year versu
estim benefit foreign currenc hedg gain offset slightli weaker price growth
year-over-year addit adjust oper expens modestli higher anticip
continu increas invest area includ sale forc effort turn around
follow favor result rais impli organ growth forecast
notabl compani expect organ growth in-lin weight averag market growth rate
posit start rather prior assumpt although believ estim
consensu alreadi reflect addit lower adjust tax rate assumpt
although compani plan use tax save reinvest sale forc
expans particularli special sale repres initi effort acceler
revenu growth plan reinvest led lower adjust oper margin outlook
inc hip organ growth analysi reflect pro forma result zimmer biomet compani report northcoast inc quarterli total compani price growth year-over-year compani lower half prior rang versu previous increas low end
adjust ep guidanc
continu expect level adjust oper margin expans said compani
anticip adjust gross margin declin level given magnitud benefit
realiz foreign currenc hedg gain year bp adjust gross margin contribut
current expect continu
rais adjust ep estim reflect improv organ growth
adjust tax rate assumpt also lower adjust ep forecast compani
reflect less adjust oper margin expans
summari expect low head earn releas given lacklust joint
replac result mid-jun announc cfo florin decis retir given backdrop
modestli better-than-consensu result includ sign improv compani key knee implant
 divis clear posit said view risk/reward balanc mix
follow stock run-up friday maintain neutral rate
guidanc earn earn callrevenu growth yr/yr flat currenc growth yr/yr constant currenc growth yr/yr organ growth yr/yr acquisit growth oper tax ep growth yr/yr compani report northcoast research estim
inc annual incom statement analysi adjust northcoast research million except percentag per share gross gross sg sg oper oper net interest incom net interest incom incom incom incom tax minor incom extra incom extra extra net net wghd com share ep ep growth ep growth exclud amort intang asset adjust ep start compani report northcoast research estim disclosur
